Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Baylor College of Medicine
Sponsor:
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine
Texas Children's Hospital
The Methodist Hospital System
National Cancer Institute (NCI)
Information provided by (Responsible Party):
George Carrum, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT01333046
First received: April 7, 2011
Last updated: September 21, 2016
Last verified: September 2016
  Purpose

Patients have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has come back, or may come back, or has not gone away after treatment, including the standard treatment known for these diseases. This a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.

This sort of therapy has been used previously to treat Hodgkin or non-Hodgkin lymphomas that show proof of infection with Epstein-Barr virus (EBV), the virus that causes infectious mononucleosis ("mono" or the "kissing disease"). EBV is found in cancer cells of up to half of all patients with Hodgkin's and non-Hodgkin lymphoma. This suggests that it may play a role in causing lymphoma. The cancer cells infected by EBV are able to hide from the body's immune system and escape being killed. Investigators tested whether special white blood cells, called T cells, that were trained to kill EBV-infected cells could affect these tumors, and in many patients it was found that giving these trained T cells caused a complete or partial response.

However, many patients do not have EBV in their lymphoma cells; therefore investigators now want to test whether it is possible to direct these special T cells against other types of proteins on the tumor cell surface with similar promising results. The proteins that will be targeted in this study are called tumor associated antigens (TAAs) - these are cell proteins that are specific to the cancer cell, so they either do not show or show up in low quantities on normal human cells.

In this study, we will target five TAAs which commonly show on lymphoma, called: NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. This will be done by using special types of T cells called cytotoxic T lymphocytes (CTLs) generated in the lab.

In addition, adult patients will receive a drug called 5-azacytidine before giving the T cells. We hope that the combination helps the T cells work better.


Condition Intervention Phase
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Hodgkin Disease
Biological: Antigen-Escalation Stage
Biological: Dose-Escalation Stage
Biological: 5-azacytidine and multiTAA T cells Stage
Biological: Pediatric multiTAA T cells Stage
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma

Resource links provided by NLM:


Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Assessment of patients with adverse events [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    To determine the safety of 2 intravenous injections of autologous TAA-specific cytotoxic T lymphocytes (CTLs) in patients with Hodgkin or non-Hodgkin lymphoma.

  • Number of Patients with treatment related Serious Adverse Events [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    To determine whether infusion of TAA-specific T cells targeting multiple tumor antigens in combination with 5-azacytidine is safe


Secondary Outcome Measures:
  • Obtain information on the expansion, persistence and anti-tumor effects of the adoptively-transferred TAA-specific CTLs [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Information on the expansion, persistence and anti-tumor effects of the adoptively transferred tumor-specific CTLs will be analyzed for the immunological parameters based on multimer analysis, intracellular cytokine staining and ELIspot assays to assess the frequency of cells secreting γ-IFN using the descriptive statistics such as mean, median, standard deviation at each timepoint.

  • Assessment of increasing the spectrum of epitopes/antigens [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    To determine whether CTL infusions increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).


Estimated Enrollment: 74
Study Start Date: January 2012
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Antigen-Escalation Stage
The first stage will be an "antigen-escalation" stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix.
Biological: Antigen-Escalation Stage

Antigen-Escalation Stage

Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:

Schedule One:

  • Day 0: PRAME-specific T cells
  • Day 28: PRAME- and SSX-specific T cells

Schedule Two:

  • Day 0: PRAME- and SSX-specific T cells
  • Day 28: PRAME/SSX/MAGE-specific T cells

Schedule Three:

  • Day 0: PRAME/SSX/MAGE-specific T cells
  • Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells

Schedule Four:

  • Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells
  • Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells
Other Names:
  • T cell injection
  • Tumor-specific CTL lines
Experimental: Dose-Escalation Study Stage
The second stage will be a dose-escalation study, beginning with the same total dose of cells used in the antigen escalation phase (5 x 10^6 cells/m2 x 2). This second stage will evaluate the safety of T cells specific for all 5 tumor associated antigens.
Biological: Dose-Escalation Stage

Dose-Escalation Stage

Four different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:

DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2

DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2

DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2

Other Name: TAA-CTL infusion
Experimental: 5-azacytidine and multiTAA T cells Stage
This phase will administer 5-aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with 5-azacytidine is safe, and whether CTL infusions (with or without 5-azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
Biological: 5-azacytidine and multiTAA T cells Stage

Up to 15 patients will be treated with 3 cycles of 5-aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last 5-aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10^7 cells/m2. If drug-related myelosuppression occurs 5-aza dosing will be modified, according to the following:

  1. ANC >1,000 or Platelets >50,000 (or any other grade I AE attributable to 5-aza)

    Adjustment: None

  2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to 5-aza)

    Adjustment: 50% dose reduction

  3. ANC <500 or any episode of febrile neutropenia or platelets <25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to 5-aza)

Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last 5-aza infusion

Experimental: Pediatric multiTAA T cells Stage
This phase will give patients < 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
Biological: Pediatric multiTAA T cells Stage
Patients < 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

PROCUREMENT:

  1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma.
  2. Life expectancy of 6 weeks or greater.
  3. Hgb greater than 8.0
  4. Patient and/or parent/guardian able to give informed consent.

TREATMENT:

  1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma:

    Group A:

    • with active disease:

      • in second or subsequent relapse.
      • in first relapse for indolent lymphoma after first-line therapy for relapse.
      • or first relapse if immunosuppressive chemotherapy contraindicated.
      • primary refractory disease or if persistent disease after first-line therapy of relapse.
    • or multiply relapsed patients in remission who are at a high risk of relapse).
    • or the lymphoma is a second malignancy e.g. a Richters transformation of CLL after failing front line therapy.

    OR

    Group B: Patients greater than or equal to 18 after autologous or syngeneic SCT (as adjuvant therapy).

    OR

    Group C: 5-azacytidine + multiTAA-T cells Patients greater than or equal to 18 yrs old

    • with active disease in:

      • second or subsequent relapse
      • first relapse for indolent lymphoma after first line therapy for relapse
      • first relapse if immunosuppressive chemotherapy contraindicated
    • with primary refractory disease or persistent disease after first line therapy of relapse
    • or lymphoma as a second malignancy e.g. a Richters transformation of CLL after failing front line therapy

    OR

    GROUP D: Patients <18 yrs old

    • with active disease in:

      • second or subsequent relapse
      • first relapse for indolent lymphoma after first line therapy for relapse
      • first relapse if immunosuppressive chemotherapy contraindicated
    • with primary refractory disease or persistent disease after first line therapy of relapse
    • with lymphoma as a second malignancy e.g. a Richters transformation of CLL after failing front line therapy
  2. Life expectancy of 6 weeks or greater.
  3. Pulse oximetry of more than 95% on room air in patients who previously received radiation therapy.
  4. Karnofsky/Lansky score of 50 or greater.
  5. Bilirubin 2X or less of upper limit of normal, AST 3X or less than the upper limit of normal, and Hgb >8.0 and platelets >25,000 (Group C only).
  6. Creatinine 2X or less of upper limit of normal for age.
  7. Patients should have been off other investigational therapy for one month prior to entry in this study.
  8. Patients should have been off conventional therapy for at least 1 week prior to entry in this study, including rituximab.
  9. Patient and/or parent/guardian able to give informed consent.
  10. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential should use of at least two forms of contraception unless female has had a hysterectomy or tubal ligation.

Exclusion Criteria:

PROCUREMENT:

  1. Patients with severe intercurrent infection.
  2. Patients with active HIV infection at time of procurement (can be pending at the time of blood draw).

TREATMENT:

  1. Patients with severe intercurrent infection.
  2. Patients receiving systemic corticosteroids.
  3. Pregnant breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01333046

Contacts
Contact: George Carrum, MD 713-441-1450 gcarrum@bcm.edu
Contact: Ann Leen, PhD 832-824-4690 amleen@txch.org

Locations
United States, Texas
Houston Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Contact: George Carrum, MD    713-441-1450    gcarrum@bcm.edu   
Contact: Ann Leen, PhD    832-824-4690    amleen@txch.org   
Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
Contact: George Carrum, MD    713-441-1450    gcarrum@bcm.edu   
Contact: Ann Leen, PhD    832-824-4690    amleen@txch.org   
Sponsors and Collaborators
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine
Texas Children's Hospital
The Methodist Hospital System
National Cancer Institute (NCI)
Investigators
Principal Investigator: Geoge Carrum, MD Baylor College of Medicine
  More Information

Responsible Party: George Carrum, Associate Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT01333046     History of Changes
Obsolete Identifiers: NCT01556269
Other Study ID Numbers: H-27471-TACTAL  TACTAL 
Study First Received: April 7, 2011
Last Updated: September 21, 2016
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Baylor College of Medicine:
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
CTL

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Azacitidine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on September 27, 2016